Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Next Previous
Trial Profile

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elritercept (Primary) ; Iron chelating agents
  • Indications Anaemia; Myelodysplastic syndromes; Thrombocytopenia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Keros Therapeutics

Most Recent Events

  • 10 Dec 2024 According to a Keros Therapeutics media release, company announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in patients with very low, low, or intermediate-risk myelodysplastic syndromes and one in patients with myelofibrosis at the 66th American Society of Hematology Annual Meeting and Exposition, held in person in San Diego, California and virtually from December 7-10, 2024.
  • 10 Dec 2024 Results presented in the Keros Therapeutics Media Release.
  • 05 Nov 2024 According to a Keros Therapeutics media release, data from this study presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in person and virtually from December 7 through 10, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top